IRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRadimed Corp (IRMD) is not an immediate buy for a beginner investor seeking long-term growth. While the company demonstrates strong financial performance and positive analyst sentiment, the current technical indicators and lack of significant trading signals suggest waiting for a better entry point.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 27.408, which is near oversold territory but not a clear buy signal. The stock is trading near its S1 support level of 91.666, with resistance at 94.466. Moving averages are converging, showing no clear trend.
Analyst ratings are highly positive, with multiple buy ratings and raised price targets ($116-$120). The company is uniquely positioned in its market with MRI-compatible products and international expansion opportunities. Financial performance in Q4 2025 showed strong revenue, net income, and EPS growth.
No recent news or significant trading activity from hedge funds, insiders, or Congress. Gross margin dropped slightly YoY. Technical indicators suggest bearish momentum, and no proprietary trading signals are present.
In Q4 2025, revenue increased by 17.03% YoY to $22.69M. Net income rose by 25.16% YoY to $6.44M, and EPS grew by 25% YoY to $0.50. However, gross margin dropped slightly to 75.06%, down 1.41% YoY.
Analysts are bullish, with price targets raised to $116-$120 and buy ratings maintained. Analysts cite strong product-driven upgrade cycles, international expansion, and profitability as key drivers.
